Q-omics provides the consensus-scored PPARA profile across patient tissues and cancer cell-line models. PPARA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPARA is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PPARA RNA expression shows 20,306 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where PPARA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPARA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPARA survival associations across molecular data types. PPARA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPARA RNA expression–survival associations across cancer types. High PPARA expression shows unfavorable associations in ACC, UVM and MESO, but favorable associations in KIRC, HNSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPARA RNA expression.
This table summarizes PPARA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPARA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPARA shows lower tumor expression in KIRC, THCA, BRCA, KIRP, COAD and BLCA. The KIRC box plot shows higher PPARA RNA expression in normal versus tumor tissue (log2 FC = −0.844, t-test p < 0.001).
This table shows molecular features associated with PPARA in patient tissues and cancer cell lines. In patient samples, PPARA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPARA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
